Active Ingredient(s): Drotrecogin Alfa
FDA Approved: * November 21, 2001
Pharm Company: * LILLY
Category: Anti-Inflammatory

Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized.[1] On October 25, 20... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
3 Discussions

Popular Topics

can xigris be used for nephratic syndrome patients?? detected with dengue?

my dad is a nephratic syndrome second degree patient,recently his serum creatinine level was 1.4,was having fever with l...

xigris side effects

severe blood loss timescale between given xigris one day week or month...